Thalidomide hypersensitivity in AIDS

Williams, IG; Weller, I.V.D.; Malin, Adam; Anderson, J.; Waters, Michael F.

doi:10.1016/0140-6736(91)91221-f

Cited by 46 publications

(24 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Drowsiness, its original intended use, is likely the most frequently observed side-effect [9]. Peripheral neuropathy is common and estimated to affect 15%-50% of HIV patients using it [10].…”

Section: Introductionmentioning

confidence: 99%

Thalidomide‐associated hepatitis: A case report

Fowler

Imrie

2001

American J Hematol

View full text Add to dashboard Cite

We report a case of hepatitis in a 58-year-old woman being treated with thalidomide for end-stage plasma cell leukemia. The patient had a medical history including chronic stable hepatitis C infection. At diagnosis there was a severe anemia, thrombocytopenia, hypercalcemia, IgG paraproteinemia, peripheral blood myeloma cells, and a marrow plasmacytosis with lytic bony lesion. The disease was refractory to standard chemotherapy, and she was treated with oral thalidomide. Within 1 week she became jaundiced and developed a marked transaminitis. This promptly resolved upon cessation of thalidomide alone. Thalidomide has recently enjoyed renewed interest as a treatment in many disorders, including plasma cell leukemia. To our knowledge, this is the first reported case of thalidomide-associated hepatotoxicity. Although the mechanism of its actions on the liver are uncertain, it is possible that thalidomide acts as a direct hepatotoxin or as an immuno-modulator, altering the activity of chronic viral hepatitis. We present this case to increase awareness of a new potential side effect of thalidomide as its clinical indications expand. Am. J. Hematol. 66:300-302, 2001.

show abstract

Section: Introductionmentioning

confidence: 99%

Thalidomide‐associated hepatitis: A case report

Fowler

Imrie

2001

American J Hematol

View full text Add to dashboard Cite

show abstract

“…Thalidomide may produce remission or reduction in symptoms of RAS (Mascaro et al, 1979;Grinspan, 1985;Eisenbud et al, 1987;Grinspan et al, 1989;Nicolau and West, 1990;Revuz et al, 1990;Gunzler, 1992); however, this treatment is not without its dangers. Thalidomide therapy should be considered when patients have episodes of profound ulceration, and perhaps limited to persons with HIV-related ulceration, although thalidomide hypersensitivity can occur in HIV disease (Williams et al, 1991). Aside from teratogenicity, thalidomide can give rise to several other serious (e.g., irreversible polyneuropathy) side-effects.…”

Section: Management (A) Diagnosismentioning

confidence: 99%

Recurrent Aphthous Stomatitis

Porter

Scully

Pedersen

1998

Critical Reviews in Oral Biology & Medicine

251

143

View full text Add to dashboard Cite

show abstract

“…Drug reactions, including toxic epidermal necrolysis, are reported with thalidomide but were not seen in this study. 21,39,40 A recent review of thalidomide for the treatment of multiple myeloma cautions that thalidomide combined with dexamethasone or drugs known to cause toxic epidermal necrolysis can result in severe skin reactions. 29 There is evidence of increased HIV replication in HIV-infected patients with aphthous ulcers who took thalidomide.…”

Section: Commentmentioning

confidence: 99%

“…12 Thalidomide is associated with teratogenicity (phocomelia), [13][14][15] peripheral neuropathy, [16][17][18][19][20] and drug reactions. 10,[21][22][23] Because drug reactions and peripheral neuropathies are prevalent in HIV-infected subjects 24 and because peripheral neuropathies have been reported in up to 70% of immunocompetent patients with PN, [25][26][27] this study is particularly relevant in examining the efficacy and safety of thalidomide in a group of HIV-infected individuals with PN.…”

mentioning

confidence: 99%